Skip to main content

sGC stimulators in experimental pulmonary hypertension

Remodeling of blood vessels shares many similarities such as medial wall thickening, neointimal formation and endothelial dysfunction. The nitric oxide (NO) – soluble guanylate cyclase (sGC) pathway plays a central role in maintaining physiological organ function. Alterations of this pathway have been attributed to be centrally involved in the course of several cardiopulmonary diseases and are subject to the development of new therapeutic agents. Among the most recent approaches stimulators of the soluble guanylate cyclase, e.g. BAY 41–2272 or BAY 63–2521 and activators e.g BAY 58–2667 proved anti-remodeling efficacy in two well established models of chronic pulmonary hypertension (hypoxia and monocrotaline-induced pulmonary hypertension). These compounds improve pulmonary hemodynamics not only symptomatically (as previously shown for many other substances) but also reversed vascular remodeling. Targeting sGC is of considerable interest as stimulators and activators of this enzyme represent a new class of drugs complementary to currently established therapies for chronic vascular disorders (e.g. PDE inhibitors, ACE inhibitors, endothelin receptor antagonists, etc.).

Author information



Corresponding author

Correspondence to Ralph Theo Schermuly.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Schermuly, R.T., Ghofrani, H.A. & Grimminger, F. sGC stimulators in experimental pulmonary hypertension. BMC Pharmacol 7, S3 (2007).

Download citation


  • Nitric Oxide
  • Pulmonary Hypertension
  • Vascular Remodel
  • Medial Wall
  • Vascular Disorder